The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.
Male or female participants with Body Mass Index (BMI) ≥ 30 kg/m² OR BMI ≥ 27 kg/m² to < 30 kg/m² with at least one weight-related comorbidity
History of at least one self-reported unsuccessful dietary effort to lose body weight
HbA1c ≥ 48 mmol/mol (6.5%) at screening
History of Type 1 or Type 2 Diabetes
Self-reported change in body weight > 5 kg within 90 days prior to screening
Previous or planned obesity treatment with surgery (excluding liposuction, cryolipolysis, or abdominoplasty if performed > 1 year prior to or during screening)
6
Treatment groupsSee each treatment group below.
Hoffmann-La Roche
Lead sponsor
Zealand Pharma
Collaborator